Purchase Order 75N92025P00347

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $15,440 firm fixed-price purchase order to Proteogenix, a biotechnology manufacturer based in Schiltigheim, France, on August 28, 2025. The contract, which utilizes no set-aside designation, requires delivery of a phage library to support the NHLBI's Cellular and Molecular Therapeutics Laboratory in conducting genetic analysis experiments. The phage library will facilitate the laboratory's ongoing research into hematopoietic stem cell (HSC) therapy with gene modification capabilities, with work to be completed by November 1, 2025.

This award represents part of Proteogenix's established relationship with NHLBI, where the vendor has demonstrated specialized expertise in advanced laboratory screening and research support services for gene therapy development. The company's prior contract work with NHLBI has included phage-display library screening and VHH antibody screening services, positioning it to deliver the sophisticated biotechnological products and support required for this HSC therapy research initiative. As a registered SAM.gov vendor in good standing, Proteogenix continues to support NHLBI's Center for Molecular Therapeutics and Bioanalytics in advancing innovative therapeutic approaches through targeted genetic research methodologies.